CDNF and CDNF variants- novel therapy for ALS

Bidragets beskrivning

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, where motoneurons selectively die, leading to muscle atrophy and paralysis. There is currently no therapy for ALS. Patients die on average 3-5 years from time of diagnosis. Endoplasmic reticulum (ER) stress plays an important role in the pathophysiology of ALS. CDNF is a novel ER stress regulating protein and a promising drug candidate for ALS. A single injection of CDNF increases survival, improves motor coordination, protects MNs in spinal cord and reduces ER stress in SOD1 mouse model of ALS. In this project I will 1) identify the effect of chronic intraventricular infusion of CDNF in TDP43 rats and mice 2) Test and compare the therapeutic effect of CDNF variant and CDNF in vitro in MN cultures and in genetic models of ALS in vivo; and 3) Study how CDNF regulates ER stress in MNs from animal models of ALS and MNs generated from ALS patient-derived iPS cells, and effects on SOD1 and TDP-43 protein aggregation
Visa mer

Startår

2017

Slutår

2022

Beviljade finansiering

Merja Voutilainen Orcid -palvelun logo
434 485 €

Andra beslut

335803
Akademiforskarens forskningskostnader(2020)
200 000 €
314233
Akademiforskarens forskningskostnader(2017)
330 000 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiforskare

Övriga uppgifter

Finansieringsbeslutets nummer

309708

Vetenskapsområden

Neurovetenskaper

Forskningsområden

Neurotiede

Identifierade teman

brain, neuroscience